Angelo Ghirarduzzi Selected Research

Fluxum

2/2014

Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Angelo Ghirarduzzi Research Topics

Disease

13	Venous Thromboembolism 01/2018 - 10/2006
11	Venous Thrombosis (Deep-Vein Thrombosis) 01/2016 - 04/2004
7	Thrombosis (Thrombus) 01/2021 - 07/2007
6	Pulmonary Embolism 01/2016 - 10/2006
5	Hemorrhage 01/2021 - 09/2002
3	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 06/2010
3	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2021 - 12/2007
3	Neoplasms (Cancer) 11/2014 - 11/2009
3	Thromboembolism 02/2014 - 10/2006
2	Myocardial Infarction 01/2018 - 03/2010
2	Ischemic Stroke 01/2018 - 07/2007
2	Atrial Fibrillation 01/2018 - 01/2017
2	Embolism (Embolus) 01/2017 - 07/2007
2	Vascular Diseases (Vascular Disease) 06/2010 - 11/2005
1	Hemophilia A (Haemophilia) 01/2022
1	Paraganglioma (Paragangliomas) 01/2020
1	Fatigue 01/2020
1	Headache (Headaches) 01/2020
1	Pheochromocytoma 01/2020
1	Polycythemia (Erythrocytosis) 01/2020
1	Stroke (Strokes) 01/2017
1	Varicose Veins (Varicose Vein) 02/2014
1	Obesity 06/2010
1	Hypertension (High Blood Pressure) 06/2010
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 06/2010
1	Chronic Obstructive Pulmonary Disease (COPD) 06/2010
1	Clinical Deterioration 03/2010
1	Retinal Vein Occlusion 02/2010
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2005

Drug/Important Bio-Agent (IBA)

10	fibrin fragment D (D-dimer)IBA 01/2016 - 10/2006
5	AnticoagulantsIBA 01/2017 - 09/2002
4	Vitamin K FDA Link 01/2017 - 10/2006
3	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 01/2017
3	Prothrombin (Factor II)IBA 03/2013 - 04/2004
3	factor V LeidenIBA 03/2013 - 04/2004
2	RivaroxabanIBA 01/2021 - 01/2018
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2015 - 02/2010
2	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 11/2014 - 02/2014
2	parnaparinIBA 02/2014 - 02/2010
2	SuspensionsIBA 06/2010 - 01/2010
2	Fumigant 93 (D-D)IBA 01/2010 - 11/2009
1	Factor VIII (Coagulation Factor VIII)IBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	AutoantibodiesIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	Dabigatran FDA Link 01/2021
1	EnzymesIBA 01/2020
1	Erythropoietin FDA Link 01/2020
1	Hemoglobins (Hemoglobin)IBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	Chromogranin AIBA 01/2020
1	edoxabanIBA 01/2017
1	FluxumIBA 02/2014
1	TESIBA 10/2011
1	Tenecteplase FDA Link 03/2010
1	Heparin (Liquaemin)FDA LinkGeneric 03/2010
1	Lupus Coagulation Inhibitor (Lupus Anticoagulant)IBA 12/2007
1	2,5-dichloro-4-bromophenol (B 2)IBA 07/2007
1	HomocysteineIBA 11/2005
1	Factor V (Coagulation Factor V)IBA 04/2004

Therapy/Procedure

3	Therapeutics 11/2009 - 12/2007
1	Adrenalectomy 01/2020
1	Aftercare (After-Treatment) 12/2007